SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Sick Visit — Charlotte Brontë

PatientCharlotte Brontë
Date of birth1987-04-21
IdentifiersMRN HR-NI025-SYN; SSN (made up) 000-25-3804
Document date2026-01-29
AuthorEleanor Thwaite, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Vomiting everything for a day and a half, dizzy when she stands, and passing little urine. [S]

History of Present Illness

Ms. Brontë is a 38-year-old woman in her first pregnancy, at 9 weeks 3 days by a 7-week dating scan, with moderate nausea and vomiting of pregnancy treated for two weeks with doxylamine-pyridoxine, raised nine days ago to four tablets a day, and metoclopramide 10 mg three times a day added at the same visit. She was a little better for two days and then worse. For the last 36 hours she has kept down neither fluids nor tablets and has vomited eight to ten times a day, including bile. She feels faint when she stands, her mouth is dry, and she has passed a small amount of dark urine twice today. She has had no abdominal pain, fever, diarrhea, headache, visual change, confusion, unsteadiness, palpitations, or tremor, and no vaginal bleeding. Metoclopramide has caused no restlessness or abnormal movements. She weighs 42.6 kg, 7.4 percent below her pre-pregnancy weight of 46.0 kg. Her PUQE-24 score today is 14 (severe). A family member drove her in. [S]

ElementDetail
OnsetNausea and vomiting from about 6 weeks; unable to keep fluids down for 36 hours
SeverityPUQE-24 score 14 (severe); vomiting eight to ten times a day
Associated signs and symptomsFaint on standing, dry mouth, little dark urine
Pertinent negativesNo pain, fever, diarrhea, bleeding, headache, confusion, unsteadiness, or visual change
Treatment so farDoxylamine-pyridoxine four tablets a day and metoclopramide 10 mg three times a day; tablets now vomited
Weight42.6 kg, 7.4 percent below her pre-pregnancy weight

Review of Systems

SystemResultFinding
ConstitutionalPositiveWeak and lightheaded on standing; no fever
GastrointestinalPositiveVomiting eight to ten times a day; no abdominal pain, diarrhea, or blood in the vomit
GenitourinaryPositiveSmall amounts of dark urine; no burning or frequency; no vaginal bleeding
NeurologicalNegativeNo headache, confusion, double vision, or unsteadiness
EndocrineNegativeNo palpitations, tremor, or heat intolerance
PsychiatricPositiveLow and frightened by how ill she feels; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe)One tablet by mouth dailyOral route2026-01-13activeS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtimeTwo tablets by mouth at bedtimeOral route2026-01-13 to 2026-01-20completedS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day)One tablet in the morning, one mid-afternoon, and two at bedtimeOral route2026-01-20activeS
Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before mealsOne tablet by mouth three times a day, 30 minutes before mealsOral route2026-01-20 to 2026-01-29completedS
Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours1000 mL over 8 hours, guided by daily electrolytesIntravenous route2026-01-29 to 2026-02-01completedS
Thiamine 100 mg intravenously daily, the first dose before any dextrose100 mg intravenously once daily; first dose before any dextrose-containing fluidIntravenous route2026-01-29 to 2026-02-01completedS
Ondansetron 4 mg intravenously every 8 hours4 mg by slow intravenous injection every 8 hoursIntravenous route2026-01-29 to 2026-02-01completedS
Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg)20 mg (0.2 mL) subcutaneously once daily while in hospitalSubcutaneous route2026-01-29 to 2026-02-01completedS
Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once2 g intravenously over 1 hour, one doseIntravenous route2026-01-29 to 2026-01-29completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-01-29Body height152cmS
2026-01-29Body weight42.6kgS
2026-01-29Body mass index (BMI) [Ratio]18.4kg/m2S
2026-01-29Systolic blood pressure96mm[Hg]S
2026-01-29Diastolic blood pressure60mm[Hg]S
2026-01-29Heart rate108/minS
2026-01-29Respiratory rate16/minS
2026-01-29Body temperature36.9CelS
2026-01-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-29Hemoglobin [Mass/volume] in Blood14.1g/dL11-15.5 g/dLNormalS
2026-01-29Sodium [Moles/volume] in Serum or Plasma133mmol/L135-145 mmol/LLowS
2026-01-29Potassium [Moles/volume] in Serum or Plasma3.1mmol/L3.5-5.1 mmol/LLowS
2026-01-29Chloride [Moles/volume] in Serum or Plasma94mmol/L98-107 mmol/LLowS
2026-01-29Carbon dioxide, total [Moles/volume] in Serum or Plasma31mmol/L22-29 mmol/LHighS
2026-01-29Urea nitrogen [Mass/volume] in Serum or Plasma21mg/dL6-20 mg/dLHighS
2026-01-29Creatinine [Mass/volume] in Serum or Plasma0.71mg/dL0.4-0.9 mg/dLNormalS
2026-01-29Glucose [Mass/volume] in Serum or Plasma68mg/dL70-99 mg/dLLowS
2026-01-29Magnesium [Mass/volume] in Serum or Plasma1.6mg/dL1.7-2.2 mg/dLLowS
2026-01-29Phosphate [Mass/volume] in Serum or Plasma2.6mg/dL2.5-4.5 mg/dLNormalS
2026-01-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma66U/L7-35 U/LHighS
2026-01-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma49U/L10-35 U/LHighS
2026-01-29Thyrotropin [Units/volume] in Serum or Plasma0.03m[IU]/L0.1-2.5 mIU/LLowS
2026-01-29Thyroxine (T4) free [Mass/volume] in Serum or Plasma2.1ng/dL0.8-1.8 ng/dLHighS
2026-01-29Ketones [Mass/volume] in Urine by Test strip80mg/dL<=0 mg/dLHighS

Physical Exam

Vital signs recorded on 2026-01-29; see the Vital Signs section. [S]

SystemFinding
GeneralSlight, pale, and tired; retching into a bowl; alert
HydrationDry mucous membranes; capillary refill 3 seconds; blood pressure 96/60 mmHg and pulse 108 seated, 88/56 mmHg and 124 standing
NeckThyroid not enlarged; no bruit
EyesNo proptosis or lid lag; no nystagmus
CardiovascularSinus tachycardia; no murmur
AbdomenSoft and non-tender; no guarding; uterus not yet palpable
NeurologicalOriented; normal eye movements; no ataxia; no tremor
FetalBedside ultrasound: fetal cardiac activity present

Problems

ProblemClinical statusVerificationCodeProvenance
First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 dayactiveconfirmed O09.519S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019).
Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarumresolvedconfirmed O21.9S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R.
Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14activeconfirmed O21.1S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis.
Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment neededactiveconfirmed O99.281S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness.

Assessment and Plan

Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium (Green-top Guideline No. 37a) (2015); 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (2017)

Follow-up: Prenatal review about ten days after admission, with electrolytes repeated within a week of discharge. Return the same day if vomiting returns and she cannot keep fluids down for 24 hours, if she feels faint, or if confusion, unsteadiness, or double vision develop. Next scheduled visit 2026-02-10: prenatal visit at 11 weeks: nausea and vomiting review and cell-free DNA screening. [S]